Literature DB >> 25838402

Clinical relevance of CYP3A5 genotype on maraviroc exposures.

Manoli Vourvahis1, Lynn McFadyen2, Jayvant Heera2, Andrew Clark2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25838402      PMCID： PMC4407706          DOI： 10.1124/dmd.115.063321

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN： 0090-9556            Impact factor:   3.922


× No keyword cloud information.
  14 in total

1.  A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc.

Authors:  Maria C Rosario; Bill Poland; John Sullivan; Mike Westby; Elna van der Ryst
Journal:  J Acquir Immune Defic Syndr       Date:  2006-06       Impact factor: 3.731

2.  Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

Authors:  Gerd Fätkenheuer; Anton L Pozniak; Margaret A Johnson; Andreas Plettenberg; Schlomo Staszewski; Andy I M Hoepelman; Michael S Saag; Frank D Goebel; Jürgen K Rockstroh; Bruce J Dezube; Tim M Jenkins; Christine Medhurst; John F Sullivan; Caroline Ridgway; Samantha Abel; Ian T James; Mike Youle; Elna van der Ryst
Journal:  Nat Med       Date:  2005-10-05       Impact factor: 53.440

3.  Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.

Authors:  Marika T Granfors; Jun-Sheng Wang; Lauri I Kajosaari; Jouko Laitila; Pertti J Neuvonen; Janne T Backman
Journal:  Basic Clin Pharmacol Toxicol       Date:  2006-01       Impact factor: 4.080

Review 4.  Maraviroc: pharmacokinetics and drug interactions.

Authors:  Samantha Abel; David J Back; Manoli Vourvahis
Journal:  Antivir Ther       Date:  2009

5.  CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

Authors:  Yanhui Lu; Edward J Fuchs; Craig W Hendrix; Namandjé N Bumpus
Journal:  Drug Metab Dispos       Date:  2014-08-12       Impact factor: 3.922

6.  Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.

Authors:  David A Cooper; Jayvant Heera; James Goodrich; Margaret Tawadrous; Michael Saag; Edwin Dejesus; Nathan Clumeck; Sharon Walmsley; Naitee Ting; Eoin Coakley; Jacqueline D Reeves; Gustavo Reyes-Teran; Mike Westby; Elna Van Der Ryst; Prudence Ive; Lerato Mohapi; Horacio Mingrone; Andrzej Horban; Frances Hackman; John Sullivan; Howard Mayer
Journal:  J Infect Dis       Date:  2010-03-15       Impact factor: 5.226

Review 7.  Genetic variability in CYP3A5 and its possible consequences.

Authors:  Hong-Guang Xie; Alastair J J Wood; Richard B Kim; C Michael Stein; Grant R Wilkinson
Journal:  Pharmacogenomics       Date:  2004-04       Impact factor: 2.533

8.  Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

Authors:  Samantha Abel; Timothy M Jenkins; Lyndsey A Whitlock; Caroline E Ridgway; Gary J Muirhead
Journal:  Br J Clin Pharmacol       Date:  2008-04       Impact factor: 4.335

9.  Maraviroc for previously treated patients with R5 HIV-1 infection.

Authors:  Roy M Gulick; Jacob Lalezari; James Goodrich; Nathan Clumeck; Edwin DeJesus; Andrzej Horban; Jeffrey Nadler; Bonaventura Clotet; Anders Karlsson; Michael Wohlfeiler; John B Montana; Mary McHale; John Sullivan; Caroline Ridgway; Steve Felstead; Michael W Dunne; Elna van der Ryst; Howard Mayer
Journal:  N Engl J Med       Date:  2008-10-02       Impact factor: 91.245

10.  Assessment of Maraviroc Exposure-Response Relationship at 48 Weeks in Treatment-Experienced HIV-1-Infected Patients in the MOTIVATE Studies.

Authors:  P Jacqmin; J R Wade; B Weatherley; E Snoeck; S Marshall; L McFadyen
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-08-14
View more
  1 in total

1.  Response to "clinical relevance of CYP3A5 genotype on maraviroc exposures".

Authors:  Yanhui Lu; Edward J Fuchs; Craig W Hendrix; Namandjé N Bumpus
Journal:  Drug Metab Dispos       Date:  2015-05       Impact factor: 3.922
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.